Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials In Review: Big Hits And Misses In 2018

Executive Summary

Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.

Advertisement

Related Content

AZ Goes Into The MYSTIC And Finds Positives For Imfinzi
Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval
Mystic Miss Not Make Or Break For Imfinzi
IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel